Ion Channel Application Notes
Using non-radioactive assay as a screening tool for membrane protein modulators is well-documented in scientific literature and has been widely used for studying the potassium channel family. The same principle of the nonradioactive Rb+ assay can be easily applied to more membrane protein targets than currently validated. The following publications represent a partial collection of ICR applications useful to both pharmaceutical labs and academic institutions. Please contact Aurora for further information regarding your specific protocol requirements.
Target-Specific Publications
Emerging Applications
Electrogenic membrane proteins are diverse in both structure and function. This heterogeneity is vital to serving a wide array of physiological roles. At Aurora, we take pride in tailoring our ICR assay to fit our clients’ needs. We make a sincere effort to get out in front of the field and pioneer new means of tackling challenging problems. Our scientists are currently collaborating with pharmaceutical and academic partners to develop new and effective ICR-based assays for use in transporter, natural product, and cancer biomarker study.
Applications
Publications
- • Nonradioactive Rubidium Efflux Assay Technology for Screening of Ion Channels（Georg C. Terstappen）
- • Ion Flux and Ligand Binding Assays for Analysis of Ion Channels（Georg C. Terstappen）
- • Development and validation of HTS assay for screening the calcium-activated chloride channel modulators in TMEM16A stably expressed CHO cells
- • Screening technologies for ion channel drug discovery
- • Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel
- • High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5
- • Cellular HTS Assays for Pharmacological Characterization of Na V 1.7 Modulators
- • Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants
- • Evaluation of the Rubidium Efflux Assay for Preclinical Identification of hERG Blockade
- • Characterization of a hERG Screen Using the IonWorks HT: Comparison to a hERG Rubidium Efflux Screen
- • Development of an HTS Assay for Na , K -ATPase Using Nonradioactive Rubidium Ion Uptake
- • Rb + Flux through hERG Channels Affects the Potency of Channel Blocking Drugs: Correlation with Data Obtained Using a High-Throughput Rb + Efflux Assay
- • Atomic Absorption Spectroscopy in Ion Channel Screening
- • Nonradioactive Rubidium Ion Efflux Assay and Its Applications in Drug Discovery and Development
- • Validation of an Atomic Absorption Rubidium Ion Efflux Assay for KCNQ/M-Channels Using the Ion Channel Reader 8000
- • High Throughput Assay Technologies for Ion Channel Drug Discovery
- • A High Throughput Screening Techno logy-Overcoming Bottlenecks in Ion Channel Drug Targets
- • A medium-throughput functional assay of KCNQ2 potassium channels using rubidium efflux and atomic absorption spectrometry